Telix Pharmaceuticals Limited (TLX)
| Market Cap | 5.18B |
| Revenue (ttm) | 430.80M |
| Net Income (ttm) | 32.82M |
| Shares Out | 334.23M |
| EPS (ttm) | 0.10 |
| PE Ratio | 157.79 |
| Forward PE | 89.57 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,563 |
| Open | 16.00 |
| Previous Close | 16.39 |
| Day's Range | 15.60 - 17.57 |
| 52-Week Range | 14.44 - 19.99 |
| Beta | 2.38 |
| Analysts | Strong Buy |
| Price Target | 21.00 (+32.74%) |
| Earnings Date | n/a |
About TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis o... [Read more]
Analyst Forecast
According to one analyst, the rating for TLX stock is "Strong Buy" and the 12-month stock price forecast is $21.0.
News
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
MELBOURNE, Australia, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new asset...
Telix ADSs Commence Trading on Nasdaq
MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) announces that its American Depository Shares (ADSs) have commenced tr...